Brian McKelligon Form 3 Akoya Biosciences / Brian McKelligon ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

McKelligon Brian

(Last) (First) (Middle)

100 CAMPUS DRIVE, 6TH FLOOR

(Street)

MARLBOROUGH MA 01752

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/20/2021

3. Issuer Name and Ticker or Trading Symbol
Akoya Biosciences, Inc. [ AKYA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
President/CEO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities are beneficially owned.	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	11/09/2027	Common Stock	353,129	0.3	D
Employee Stock Option (Right to Buy)	(2)	11/09/2027	Common Stock	117,709	0.3	D
Employee Stock Option (Right to Buy)	(3)	05/02/2029	Common Stock	248,318	0.44	D
Employee Stock Option (Right to Buy)	(2)	05/02/2029	Common Stock	82,772	0.44	D
Employee Stock Option (Right to Buy)	(4)	03/24/2031	Common Stock	214,592	16.12	D

Explanation of Responses:

1. The option vested as to one-fourth of the shares on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on July 14, 2018, until fully vested, subject to reporting person's continuous employment.

2. Such performance-based option shares were issued in 2017 and 2019, respectively. In 2020, the options vested as performance conditions were determined to have been achieved.

3. The option vested as to one-fourth (1/4) of the shares on September 26, 2019 with the remaining shares vesting in 36 equal monthly installments beginning on September 26, 2019, until fully vested, subject to reporting person's continuous employment.

4. The option shall vest with respect to (1/4) of such shares on March 22, 2022 and the remaining shares shall vest in 36 equal monthly installments beginning on March 22, 2022, until fully vested, subject to reporting person's continuous employment.

Remarks:

Exhibit 24.1 Power of Attorney

	/s/ Brian McKelligon, Joseph Driscoll, Attorney-in-Fact	04/20/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.